חוב כולל להון Teknova (TKNO)

Alpha Teknova, Inc. (TKNO) produces biotechnology components while facing risks from declining venture capital investments and raw material price volatility. This price chart reflects a total debt-to-equity ratio of 0.43. Stable demand for medical research renders the company a defensive asset, and unwavering trust within the B2B sector confirms its status as a reliable supplier of ultra-pure reagents for pharmaceuticals.

High capital expenditures for launching Alpha Teknova, Inc. (TKNO) plants create significant operating leverage. Analyzing the capital structure via the debt-to-equity ratio allows for an assessment of the issuer's financial stability. This metric compares total liabilities to net asset value, determining the degree of reliance on debt financing. An increase in this metric signals risks in the event of capacity underutilization, while a decrease in the ratio confirms a transition toward self-sufficiency.